Can cognitive technology assist with melanoma identification?
29 June 2016
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology – sometimes called ‘artificial intelligence’.
Melanoma Institute Australia operates the world’s largest melanoma research and treatment facility, and controls the largest melanoma research database in the world. “Research that enables the earlier detection of melanoma is likely to save more lives in the future,” says Professor Graham Mann, Research Director at Melanoma Institute Australia. “The five-year survival rate for melanoma is only 64 percent once the disease reaches the lymph nodes. However this rises to 95 percent if detected before then. Diagnosing melanoma with the naked eye is only about 60 percent accurate, but dermoscopy can lift that to over 80 percent. Research using automated analysis of images could provide the next gain in accuracy, especially where dermoscopy is hard to access.”
Using advanced visual analytics IBM Research will conduct retrospective analysis on de-identified data, which will include access to more than one million images as well as text based clinical notes in an effort to improve the accuracy of its machine learning algorithms. IBM’s cognitive technology would aim to learn to understand skin cancers such as melanoma, basal cell carcinoma and squamous cell carcinoma using lower resolution clinical images, with a goal of similar accuracy to what can be achieved with dermoscopy images.
Dr. Joanna Batstone, Vice President and Lab Director, IBM Research – Australia said, “Cognitive computing has the ability to process vast amounts of complex data including images and text very quickly, something that isn’t possible by current manual methods. Another major benefit of the self-learning technology is that it improves as more and more data is fed into it. This initiative could inform future research and, potentially, the development of offerings that could have enormous implications for both the Australian public and the health system.”
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.